Literature DB >> 10830918

Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery.

M Seki1, K Mizushige, T Ueda, M Kitadai, H Matsuo.   

Abstract

Although the effects of phosphodiesterase III (PDE III) inhibitors as vasorelaxants have been well documented, there are only few data on the wall response of different arteries. We evaluated the artery-specific effect of olprinone (OP), one of the PDE III inhibitors, on the major branches of human arteries and peripheral circulation. In 14 healthy subjects (average age: 57.5 +/- 21.2 years), systolic and diastolic diameters (Ds and Dd, respectively) and the time velocity integral (VI) of flow velocity patterns were measured by M-mode and Doppler echocardiography in the carotid artery (CA), the ascending aorta (asAo), the abdominal aorta (abAo), and the left ventricular outflow tract. Blood pressure (BP) was simultaneously measured using a cuff sphygmomanometer. Measurements were taken before and 20min after a bolus injection of OP (0.2 microg/kg). Distensibility (Ds - Dd), stiffness parameter beta (In(systolic BP/diastolic BP)/(Ds/Dd - 1)), cardiac output (CO: (Flow Area) x VI x HR at left ventricular outflow), selective flow volume (FV: (Flow Area) x VI x HR at CA or abAo), and vascular resistance (VR: mean BP/(CO or FV)) were then calculated. The distensibility increased significantly after OP administration (P = 0.0015), but that of the asAo or abAo did not change. Although there was a significant increase in CO (P = 0.001) and a significant decrease in systemic VR (P = 0.001) following OP administration, the FV and VR of both CA and abAo did not change significantly. The selectiveness of the effect of OP was demonstrated in terms of the CA wall distensibility. This was thought to be attributable to the differences in the structural components or the reactivity of smooth muscle cells to OP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10830918     DOI: 10.1007/bf01747851

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  31 in total

1.  Relationship between ultrasound assessment of arterial wall properties and blood pressure.

Authors:  T Wada; K Fujishiro; T Fukumoto; S Yamazaki
Journal:  Angiology       Date:  1997-10       Impact factor: 3.619

2.  Effect of lisinopril and metoprolol on arterial distensibility.

Authors:  M Barenbrock; C Spieker; A P Hoeks; W Zidek; K H Rahn
Journal:  Hypertension       Date:  1994-01       Impact factor: 10.190

3.  Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021.

Authors:  M Miyahara; M Ito; H Itoh; T Shiraishi; N Isaka; T Konishi; T Nakano
Journal:  Eur J Pharmacol       Date:  1995-09-15       Impact factor: 4.432

4.  Stiffness and elastic behavior of human intracranial and extracranial arteries.

Authors:  K Hayashi; H Handa; S Nagasawa; A Okumura; K Moritake
Journal:  J Biomech       Date:  1980       Impact factor: 2.712

5.  Effects of E-1020, a new cyclic AMP-specific phosphodiesterase inhibitor, on cyclic AMP and cytosolic free calcium of cultured vascular smooth muscle cells.

Authors:  M Ohoka; M Honda; S Morioka; S Ishikawa; K Nakayama; Y Yamori; K Moriyama
Journal:  Jpn Circ J       Date:  1990-06

6.  Reduced distensibility of the common carotid artery in patients treated with ergotamine.

Authors:  M Barenbrock; C Spieker; J Witta; S Evers; A P Hoeks; K H Rahn; W Zidek
Journal:  Hypertension       Date:  1996-07       Impact factor: 10.190

7.  Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease).

Authors:  P C Simons; A Algra; M L Bots; D E Grobbee; Y van der Graaf
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

8.  Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits.

Authors:  S Fujimoto; M Ohashi; A Hiramoto; Y Inoue; K Nagai; H Shiokawa; T Itoh
Journal:  Eur J Pharmacol       Date:  1998-07-24       Impact factor: 4.432

9.  Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors.

Authors:  H Itoh; M Kusagawa; A Shimomura; T Suga; M Ito; T Konishi; T Nakano
Journal:  Eur J Pharmacol       Date:  1993-08-10       Impact factor: 4.432

10.  Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship.

Authors:  R Murakami; K Sano; Y Murakami; T Shimada; S Morioka
Journal:  Int J Cardiol       Date:  1995-08       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.